GO:0062234 platelet activating factor catabolic process: Lipid Mediator Clearance, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0062234 describes the biochemical breakdown of platelet activating factor (PAF), a potent phospholipid mediator.
• PAF is inactivated primarily by PAF acetylhydrolases (PAFAH1B1, PAFAH1B2, PAFAH1B3, PLA2G7, and related enzymes) that remove the acetyl group at the sn-2 position.
• Defective PAF catabolism leads to PAF accumulation, which is linked to inflammation, atherosclerosis, and cancer.
• PAF catabolic enzymes are regulated transcriptionally and post-translationally, and their activity can be measured by mass spectrometry or enzyme assays.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect the causal roles of PAF catabolic genes in disease.
• Understanding GO:0062234 provides therapeutic targets for inflammatory and cardiovascular disorders.
Description
Platelet activating factor (PAF) is a phospholipid mediator with diverse biological actions, including platelet aggregation, inflammation, and anaphylaxis. The catabolic process that terminates PAF signaling is essential to prevent excessive or chronic inflammatory responses. GO:0062234, platelet activating factor catabolic process, encompasses the enzymatic reactions that degrade PAF, primarily through hydrolysis of the acetyl group at the sn-2 position. This process is critical for maintaining lipid mediator homeostasis and is implicated in a range of pathological conditions, from atherosclerosis to cancer. Researchers studying inflammation, cardiovascular disease, and lipid signaling require a precise understanding of PAF catabolism to identify therapeutic targets and biomarkers.
platelet activating factor catabolic process At A Glance
| GO ID | GO:0062234 |
|---|---|
| GO term | platelet activating factor catabolic process |
| Ontology | biological_process |
| Synonym | 2-O-acetyl-1-O-octadecyl-sn-glycero-3-phosphocholine catabolic process; PAF catabolic process |
| Major function | Breakdown of platelet activating factor (PAF) to terminate its signaling and prevent excessive inflammation. |
| Key enzymes | PAF acetylhydrolases (PAFAH1B1, PAFAH1B2, PAFAH1B3, PLA2G7) and related phospholipases. |
| Substrate | 2-O-acetyl-1-O-octadecyl-sn-glycero-3-phosphocholine (PAF). |
| Products | Lyso-PAF and acetate (or related metabolites). |
| Associated diseases | Atherosclerosis, inflammation, cancer, and radiation-induced injury. |
What Is GO:0062234?
GO:0062234, platelet activating factor catabolic process, is defined as the chemical reactions and pathways resulting in the breakdown of platelet activating factor, 2-O-acetyl-1-O-octadecyl-sn-glycero-3-phosphocholine. This process includes the enzymatic removal of the acetyl moiety, yielding biologically inactive lyso-PAF and acetate, and may involve further degradation steps.
Why Is platelet activating factor catabolic process Important in Cell Biology?
PAF catabolism is a key regulatory node in inflammatory and cardiovascular biology. By degrading PAF, these enzymes prevent sustained activation of PAF receptor signaling, which otherwise leads to chronic inflammation, thrombosis, and tissue damage. Dysregulation of PAF catabolic enzymes has been observed in atherosclerosis, cancer, and after radiation therapy, making this process a compelling target for therapeutic intervention.
• Prevents chronic inflammation by terminating PAF signaling.
• Protects against atherosclerosis by clearing oxidized phospholipids with PAF-like activity.
• Modulates platelet aggregation and thrombosis.
• Influences cancer progression and metastasis through lipid mediator balance.
• Plays a role in radiation-induced tissue injury and inflammation.
• Provides biomarkers for inflammatory and cardiovascular diseases.
• Offers targets for anti-inflammatory drug development.
• Essential for normal reproductive and neurological functions (e.g., PAFAH1B1 in brain development).
• Regulates allergic and anaphylactic responses.
• Contributes to the resolution of inflammation by removing pro-inflammatory lipids.
What Happens During platelet activating factor catabolic process?
Recognition and Binding of PAF
In simple terms: The enzyme finds and grabs the PAF molecule.
PAF acetylhydrolases (PAFAH1B1, PAFAH1B2, PAFAH1B3, PLA2G7) specifically bind PAF, positioning the acetyl group at the sn-2 position for hydrolysis. This binding is mediated by hydrophobic and electrostatic interactions within the enzyme active site.
Hydrolysis of the Acetyl Group
In simple terms: The enzyme cuts off the acetyl group from PAF.
The catalytic mechanism involves nucleophilic attack on the carbonyl carbon of the sn-2 acetyl group, releasing acetate and generating lyso-PAF. This reaction is calcium-independent for some isoforms and requires specific catalytic residues.
Release of Lyso-PAF and Acetate
In simple terms: The breakdown products are released.
Lyso-PAF, the primary product, is biologically inactive and can be further metabolized or reacylated. Acetate is released into the cellular milieu.
Further Degradation and Recycling
In simple terms: The products are either recycled or broken down further.
Lyso-PAF can be reacylated to form PAF or converted to other phospholipids, while acetate enters general metabolic pools. This step ensures complete clearance of PAF activity.
Key Genes Involved in GO:0062234 platelet activating factor catabolic process
The following genes encode enzymes and related proteins that directly participate in or regulate platelet activating factor catabolic process (GO:0062234).
| Gene | Major Role | Research Relevance |
|---|---|---|
| PAFAH1B1 | Catalytic subunit of PAF acetylhydrolase (isoform Ib) | Mutations cause lissencephaly; key for brain development |
| PAFAH1B2 | Regulatory subunit of PAF acetylhydrolase (isoform Ib) | Modulates enzyme activity; potential cancer target |
| PAFAH1B3 | Regulatory subunit of PAF acetylhydrolase (isoform Ib) | Involved in PAF homeostasis; studied in inflammation |
| PLA2G7 | Plasma PAF acetylhydrolase (Lp-PLA2) | Biomarker for cardiovascular disease; drug target |
| PLA2G4A | Cytosolic phospholipase A2, may produce PAF precursors | Linked to inflammatory diseases |
| PAFAH2 | PAF acetylhydrolase 2, intracellular | Protects against oxidative stress |
| LPCAT1 | Lysophosphatidylcholine acyltransferase, may reacylate lyso-PAF | Affects PAF levels; studied in cancer |
| LPCAT2 | Lysophosphatidylcholine acyltransferase 2 | Regulates PAF synthesis and catabolism balance |
| PLA2G10 | Secreted phospholipase A2, may degrade PAF-like lipids | Role in inflammation |
| PLA2G2A | Secreted phospholipase A2 | Associated with inflammatory bowel disease |
| PLA2G5 | Secreted phospholipase A2 | Implicated in asthma |
| PLA2G7 | Plasma PAF acetylhydrolase | Therapeutic target for atherosclerosis |
| PAFAH1B1 | PAF acetylhydrolase catalytic subunit | Model for lissencephaly |
| PAFAH1B2 | PAF acetylhydrolase regulatory subunit | Cancer research |
| PAFAH1B3 | PAF acetylhydrolase regulatory subunit | Inflammation studies |
| PLA2G4A | Cytosolic PLA2 | Inflammation and cancer |
| PLA2G6 | Calcium-independent PLA2 | Neurodegeneration |
| PLA2G7 | Lp-PLA2 | Cardiovascular risk marker |
How Is platelet activating factor catabolic process Regulated?
PAF catabolic process is regulated at multiple levels. Transcription of PLA2G7 and PAFAH genes is modulated by inflammatory cytokines and growth factors. Post-translational modifications, such as phosphorylation, can alter enzyme activity. Additionally, substrate availability and membrane lipid composition influence the rate of PAF degradation. In disease states, oxidative stress can inactivate PAF acetylhydrolases, leading to PAF accumulation.
platelet activating factor catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PLA2G7 | Atherosclerosis, cardiovascular disease | Knockout mouse, overexpression in macrophages |
| PAFAH1B1 | Lissencephaly, brain development | Knockout mouse, patient-derived iPSCs |
| PAFAH1B2 | Cancer, inflammation | Knockout cell lines, xenograft models |
| PAFAH1B3 | Inflammation | Knockout mouse, macrophage cell lines |
| PLA2G4A | Inflammatory diseases | Knockout mouse, point mutation knock-in |
Atherosclerosis and Cardiovascular Disease
PAF-like oxidized phospholipids contribute to atherosclerosis, and reduced PAF acetylhydrolase activity is associated with increased cardiovascular risk. PLA2G7 (Lp-PLA2) is a recognized biomarker and therapeutic target for atherosclerosis.
Cancer and Radiation Injury
Radiation therapy generates PAF agonists, and PAF catabolism may modulate tumor response and normal tissue injury. PAF acetylhydrolase activity has been linked to cancer progression and metastasis.
Neurodegeneration
Amyloid toxicity involves PAF signaling, and dysregulation of PAF catabolism may contribute to neurodegenerative processes. PAFAH1B1 mutations cause lissencephaly, highlighting the importance of PAF catabolism in brain development.
From platelet activating factor catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PLA2G7 increase PAF levels and inflammation? | PLA2G7 knockout mouse or cell line |
| How does PAFAH1B1 mutation affect neuronal migration? | Point mutation knock-in mouse (e.g., PAFAH1B1 R22C) |
| Can overexpression of PAFAH2 protect against oxidative stress? | Overexpression cell lines |
| What is the role of PAFAH1B2 in cancer cell proliferation? | Knockout cancer cell lines and xenografts |
| Does tagged PAFAH1B1 localize to specific subcellular compartments? | Knock-in of fluorescent tag (e.g., GFP) at endogenous locus |
| Can CRISPR activation of PLA2G7 reduce PAF-induced inflammation? | CRISPRa overexpression models |
How to Study the platelet activating factor catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| PAF acetylhydrolase activity assay | Enzyme catalytic activity | Screening for inhibitors or genetic variants |
| LC-MS/MS | PAF and lyso-PAF levels | Quantifying lipid mediator flux |
| CRISPR knockout screen | Gene essentiality for PAF catabolism | Identifying novel regulators |
| RNA-seq | mRNA expression of PAFAH/PLA2G genes | Transcriptional regulation studies |
| Western blot | Protein levels of PAF enzymes | Validating knockout or overexpression |
| Immunofluorescence | Subcellular localization | Determining organelle-specific catabolism |
| Flow cytometry | Platelet aggregation or immune cell activation | Functional readout of PAF signaling |
| ELISA | PAF or lyso-PAF in biological fluids | Biomarker discovery |
Enzymatic Activity Assays
PAF acetylhydrolase activity is measured using radiolabeled or fluorescent PAF analogs, quantifying the release of acetate or lyso-PAF. These assays are standard for assessing enzyme function in cell lysates or plasma.
Mass Spectrometry
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) enables sensitive detection and quantification of PAF and lyso-PAF in biological samples, providing direct evidence of catabolic flux.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that regulate PAF catabolism and sensitivity to PAF-induced phenotypes.
Transcriptomics and Proteomics
RNA-seq and proteomics reveal expression changes in PAF catabolic enzymes under inflammatory conditions or genetic perturbations.
How CRISPR Can Be Used to Study GO:0062234 platelet activating factor catabolic process
Knockout
CRISPR knockout of PAFAH1B1, PAFAH1B2, PAFAH1B3, or PLA2G7 in cell lines or mice abolishes PAF catabolism, leading to PAF accumulation and enhanced inflammatory responses. These models are used to study the causal role of PAF catabolism in disease.
Point Mutation
Point mutations in catalytic residues of PAF acetylhydrolases (e.g., PAFAH1B1 S47A) can be introduced to dissect enzymatic mechanism and substrate specificity. Such models help distinguish catalytic activity from non-catalytic functions.
Knock-in
Knock-in of epitope tags (e.g., FLAG, GFP) at endogenous loci allows visualization and immunoprecipitation of PAF catabolic enzymes under native regulation. Disease-associated mutations (e.g., PAFAH1B1 R22C) can also be knocked in to model lissencephaly.
Overexpression
Overexpression of PAF acetylhydrolases (e.g., PLA2G7, PAFAH2) via CRISPR activation or lentiviral delivery reduces PAF levels and protects against PAF-mediated inflammation. These models are useful for testing therapeutic potential.
How EDITGENE Supports platelet activating factor catabolic process Research
Researchers studying platelet activating factor catabolic process-related genes often need to determine whether a candidate gene is causally involved in PAF degradation, inflammatory signaling, or disease progression. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for platelet activating factor catabolic process research.
Frequently Asked Questions About platelet activating factor catabolic process
What is platelet activating factor catabolic process?
It is the biochemical breakdown of platelet activating factor (PAF), primarily by PAF acetylhydrolases, to terminate its signaling.
What genes are involved in platelet activating factor catabolic process?
Key genes include PAFAH1B1, PAFAH1B2, PAFAH1B3, PLA2G7, and related phospholipases.
What is the GO ID for platelet activating factor catabolic process?
The GO ID is GO:0062234.
How is PAF catabolism measured?
It is measured by enzymatic activity assays, mass spectrometry, or ELISA for PAF and lyso-PAF.
What diseases are linked to defective PAF catabolism?
Atherosclerosis, inflammation, cancer, and neurodegeneration are linked to defective PAF catabolism.
Which enzyme is the major plasma PAF acetylhydrolase?
PLA2G7 (Lp-PLA2) is the major plasma PAF acetylhydrolase.
Can CRISPR be used to study PAF catabolism?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to study PAF catabolic genes.
What is the role of PAFAH1B1 in disease?
PAFAH1B1 mutations cause lissencephaly, a severe brain developmental disorder.
How does radiation affect PAF catabolism?
Radiation therapy generates PAF agonists, which may overwhelm catabolic enzymes and contribute to tissue injury.
What are the products of PAF catabolism?
The main products are lyso-PAF and acetate.
Conclusion
GO:0062234, platelet activating factor catabolic process, is a critical biological process that terminates PAF signaling and prevents chronic inflammation. The enzymes involved, including PAFAH1B1, PAFAH1B2, PAFAH1B3, and PLA2G7, are regulated at multiple levels and are implicated in atherosclerosis, cancer, and neurodegeneration. CRISPR-based models are indispensable for dissecting the causal roles of these genes and for developing targeted therapies. EDITGENE provides comprehensive services to support such research.
References
- 1. Kono N et al.. 2019. Platelet-activating factor acetylhydrolases: An overview and update.. Biochim Biophys Acta Mol Cell Biol Lipids 1864(6):922-931 PMID: 30055287
- 2. Prescott SM et al.. 2000. Platelet-activating factor and related lipid mediators.. Annu Rev Biochem 69:419-45 PMID: 10966465
- 3. Chung KF. 1997. Platelet activating factor revisited.. Thorax 52(12):1019-20 PMID: 9516891
- 4. Snyder F. 1995. Platelet-activating factor: the biosynthetic and catabolic enzymes.. Biochem J 305 ( Pt 3)(Pt 3):689-705 PMID: 7848265
- 6. Sahu RP et al.. 2016. Radiation therapy generates platelet-activating factor agonists.. Oncotarget 7(15):20788-800 PMID: 26959112
- 7. Sirangelo I et al.. 2013. Amyloid toxicity and platelet-activating factor signaling.. J Cell Physiol 228(6):1143-8 PMID: 23169529
- 8. Tokumura A et al.. 2000. Platelet-activating factor (PAF)-like oxidized phospholipids: relevance to atherosclerosis.. Biofactors 13(1-4):29-33 PMID: 11237195
